ROS1 and non-small cell lung carcinoma: METex14 is observed in 3 to 4% of total NSCLC adenocarcinomas, the prevalence of which is greater or equal to some of the other oncogenic driver mutations: ROS1 (1–2%), NTRK1/2/3 (<1%), and BRAF (1–5%) [2,3,5,8,9,10,11,12].